[Therapeutic Efficacy of Qingre Jiedu and Huoxue Huayu Recipe in Prednisone-dependant Patients with Chronic Primary Immune Thrombocytopenic Purpura.]

OBJECTIVES: To observe the clinical efficacy of Qingre Jiedu and Huoxue Huayu Recipe on the prednisone-dependant patients with chronic primary immune thrombocytopenic purpura (CPITP). METHODS: Fifty prednisone-dependant CPITP patients were treated with Qingre Jiedu and Huoxue Huayu Recipe orally one dose a day,the dosage of prednisone for these patients was tapered according to the monitoring result of blood platelet count (BPC).The therapeutic efficacy in these patients was evaluated before and after Chinese medicine treatment over 4 weeks. RESULTS: After the treatment of chinese medicine,BPC was increased from (28.6±22.5) ×109 L-1 to (81.8±56.5)×109 L-1 (P<0.05).The dosage of prednisone was decreased from (28.1±15.2) mg/d to (8.0±9.4) mg/d (P<0.05).Complement response,response and no response rate were 2%,10% and 88% before Chinese medicine treatment,which were 30%, 46% and 24% after Chinese medicine treatment,respectively (P<0.05). CONCLUSIONS: Qingre Jiedu and Huoxue Huayu Recipe could be effective in the treatment of prednisone-dependant patients with CPITP,and could decrease the dosage of prednisone.

[Influence of MRD Status in Newly Diagnosed MM Patients with VGPR and Above after Treatment on Clinical Prognosis].

OBJECTIVE: To investigate the influence of MRD status in newly diagnosed MM patients with VGPR and above after treatment on clinical prognosis. METHODS: Clinical data of 210 newly diagnosed MM patients with VGPR and above after treatment in Fifth People's Hospital of Chendu city. from January 2010 to January 2018 were collected and retrospectively analyzed. The patients were divided into 2 groups: group A (152 patients with MRD-) and group B (58 patients with MRD+). The influencing factors of progression free survival and overall survival of patients were analyzed, and the correlation between MRD status and high-risk cytogenetic abnormalities, treatment plan and response to treatment were evaluated. RESULTS: There were no significant difference in clinical characteristics between the patients in 2 groups (P＞0.05). Single factor analysis showed that ASCT and MRD status were related with progression free survival of patients with newly diagnosed MM (P＜0.05). Multivariate analysis by Cox regression model showed that MRD+ persistence was the independent risk factor for progression free survival of patients with newly diagnosed MM (P＜0.05). The cumulative progression free survival rate in 2-year with follow-up of patients in group A was significantly higher than that in B group (P＜0.05). The median progression free survival time and overall survival time of patients with persistent MRD- were significantly longer than those of MRD+ (P＜0.05). The single factor analysis showed that MRD- maintenance time was the influencing factor of PFS and OS time of newly diagnosed MM patients (P＜0.05). The cumulative overall survival rate in 2-year with follow-up of patients with MRD- maintenance for 6 months was significantly higher than that of patients with MRD- maintenance for＜6 months (P＜0.05). The cumulative progression free survival rate and overall survival rate in 2 years with follow-up of patients with MRD- maintenance for ≥12 months were significantly higher than those of MRD-maintenance for ＜12 months（P＜0.05）. The median progression free survival time of patients with MRD- was significantly longer than that of patients with MRD+ who had≥ one kind of high-risk cytogenetic abnormality (P＜0.05). The MRD- rate of patients received ASCT was significantly higher than that of patients without ASCT (P＜0.05). The median progression free survival time of patients with MRD- was significantly longer than that of patients with MRD+ (P＜0.05). The maintenance time of MRD- in patients with bortezomib treatment was significantly longer than that of patients without bortezomib treatment in population with MRD- (P＜0.05). The median progression free survival time of patients with bortezomib treatment was significantly longer than patients without bortezomib treatment (P＜0.05). CONCLUSION: MRD+ maintenance in newly diagnosed MM patients with VGPR and above after treatment closely relates with poor long-term prognosis, however, the MRD- maintenance time can be used for prognosis evaluation. MRD+ suggests that patients possess the possibility of early recurrence, and dynamic monitoring of MRD status in treatment can be helpful to clinical determination of treatment opportunity for relapsed MM patients.